Jefferson Endocrinologist Talks to Everyday Health About Proposed Drug for Diabetes
Glucagon-like peptide-1, or GLP-1, are a class of medications that can help control blood sugar levels in patients with diabetes. A significant benefit of using some of the GLP-1 medications is that they can be administered less frequently than insulin. A new once-weekly GLP-1 drug, Albiglutide, was recently proposed for FDA approval.
Dr. Serge Jabbour, director of the Division of Endocrinology, Diabetes and Metabolic Diseases at Jefferson, comments on the new medication in an interview with EverydayHealth.com. He cautions that while convenience is important, GLP-1 medications do have some side effects that patients should be aware of. However, he added, "Albiglutide could help some patients because at least they have another option."
Read the full "Drugmaker Files for U.S. Approval of New Diabetes Drug" story.